Blood draw study aims to unravel clot mystery in rare blood cancers
NCT ID NCT06480591
First seen Jun 24, 2026 · Last updated Jul 14, 2026 · Updated 3 times
Summary
This study is collecting blood samples from 35 adults with a type of blood cancer called myeloproliferative neoplasm (MPN) who have a specific genetic mutation (CALR). Researchers want to understand why patients with a different mutation (JAK2) have a higher risk of dangerous blood clots. By measuring certain immune markers in the blood, they hope to find clues about the difference in clot risk.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOPROLIFERATIVE NEOPLASM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Atrium Health Levine Cancer
RECRUITINGCharlotte, North Carolina, 28204, United States
-
Wake Forest Baptist Comprehensive Cancer Center
RECRUITINGWinston-Salem, North Carolina, 27157, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug reduce bloodletting for polycythemia vera?
- Could a walk a day keep brain fog away after a stem cell transplant?
- Can a gentler chemo-radiation combo make stem cell transplants safer for blood cancers?
- Can a modified interferon rein in early myelofibrosis?
- Can pressurized oxygen boost cord blood transplants?
- New transplant recipe aims to tame Graft-Versus-Host disease